Table 1.
Baseline information of COVID‐19 severe patients enrolled in this study
| Total | Survival | Non‐survival | P value | |
|---|---|---|---|---|
| N | 73 | 53 | 20 | \ |
| Age, y | 66 (59.00‐72.30) | 64 (56.00‐71.30) | 69 (64.00‐76.50) a | .033 |
| Males | 42 (57.5%) | 27 (50.9%) | 15 (75.0%) | .109 |
| Duration from onset to admission, d | 10 (7.5‐12) | 11.0 (8.3‐13.0) | 12 (10.0‐13.0) | .442 |
| Time from admission to death, d | \ | \ | 12 (6.25‐17.5) | \ |
| Initial symptoms | ||||
| Fever | 69 (94.5%) | 49 (92.5%) | 20 (100.0%) | .569 |
| Cough | 42 (57.5%) | 27 (50.9%) | 15 (75.0%) | .109 |
| Sputum production | 3 (4.1%) | 2 (3.8%) | 1 (5.0%) | 1.000 |
| Dizziness | 3 (4.1%) | 2 (3.8%) | 1 (5.0%) | 1.000 |
| Chest tightness | 13 (17.8%) | 9 (17.0%) | 4 (20.0%) | .742 |
| Myalgia | 6 (8. 2%) | 4 (7.5%) | 2 (10.0%) | .663 |
| Tachypnea | 10 (13.7%) | 8 (15.1%) | 2 (10.0%) | .717 |
| Diarrhea | 20 (27.4%) | 14(26.4%) | 6 (30.0%) | .774 |
| Fatigue | 10(13.7%) | 6 (11.3%) | 4 (20.0%) | .446 |
| Dyspnea | 23 (31.5%) | 20 (37.7%) | 3 (15.0%) | .090 |
| Comorbidities | ||||
| Hypertension | 33 (45.2%) | 23 (43.4%) | 10 (50.0%) | .792 |
| Diabetes | 15 (20.5%) | 13 (24.5%) | 2 (10.0%) | .211 |
| Cardiovascular disease | 9 (12.3%) | 6 (11.3%) | 3 (15.0%) | .698 |
| Lung disease | 7 (9.6%) | 6 (11.3%) | 1 (5.0%) | .665 |
| Cerebral infarction | 3 (4.1%) | 2 (3.8%) | 1 (5.0%) | 1.000 |
| Chronic liver disease | 2 (2.7%) | 2 (3.8%) | 0 (0.0%) | 1.000 |
| Malignant tumor | 6 (8.2%) | 4 (7.5%) | 2 (10.0%) | .663 |
| Treatments | ||||
| Antibiotics | 69 (94.5%) | 49 (92.5%) | 20 (100%) | .570 |
| Antiviral Chinese Herb | 67 (91.8%) | 48 (90.6%) | 19 (95%) | 1.000 |
| Antiviral modern drug | 73 (100%) | 53 (100%) | 20 (100%) | 1.000 |
| Corticosteroids | 62 (84.9%) | 43 (81.1%) | 19 (95%) | .270 |
| Immunoglobin | 35 (47.9%) | 22 (41.5%) | 13 (65%) | .114 |
| High flow nasal cannula | 70 (95.9%) | 51 (96.2%) | 19 (95%) | 1.000 |
| Non‐invasive mechanical ventilation | 33 (45.2%) | 13 (24.5%) | 20 (100%) a | <.001 |
| Invasive mechanical ventilation | 18 (24.7%) | 7 (13.2%) | 11 (55%) a | <.001 |
Abbreviations: COVID‐19, coronavirus disease 2019; IQR, interquartile range; N, number.
Continuous variables were presented as median and IQR; categorical variables were given as number and percentages; p values were calculated by Mann‐Whitney U test or Fisher's exact test.
a
Compared with COVID‐19 survival group, P < .05.